Table 2. Characteristics of baseline laboratory indices in metformin or insulin users.
| Characteristics | Non-metformin (N =16) | Metformin (N =25) | P-value | Non-insulin (N = 10) | Insulin (N = 35) | P-value |
|---|---|---|---|---|---|---|
| Concentrations (per day) | - | 1 (0.55 – 1.52) | NA | - | 35 (28.2 – 50.3) | NA |
| Age (years) | 58.67 ± 10.81 | 60.80 ± 12.56 | 0.518 | 52.67 ± 8.81 | 67.8 ± 9.26 | 0.038 |
| Gender (M, %) | 7 (43.7 %) | 12 (48 %) | 0.657 | 6 (60 %) | 17 (48.5 %) | |
| Comorbidities (n, %) | ||||||
| Hypertension | 7 (43.7%) | 7 (28 %) | 0.257 | 3 (30 %) | 9 (25.7%) | 0.436 |
| Cardiovascular disease | 2 (12.5%) | 4 (16 %) | 0.368 | 1 (10%) | 5 (14.2 %) | 0.813 |
| Chronic kidney disease | 7 (43.7 %) | 7 (28 %) | 0.537 | 4 (40 %) | 10 (28.5%) | 0.251 |
| Baseline laboratory indices | ||||||
| Blood glucose | 7 (5-14) | 10 (8-14) | 0.014 | 5 (4-8) | 14 (9-15) | < 0.001 |
| White blood cells | 8 (6-12) | 9 (6-10) | 0.463 | 7 (5-11) | 9 (7-12) | 0.082 |
| Lymphocytes | 1 (1-1) | 1 (1-1) | 0.666 | 1 (1-2) | 1 (1-1) | 0.430 |
| Monocytes | 0 (0-0) | 0 (0-0) | 0.040 | 0 (0-0) | 0 (0-0) | 0.368 |
| Neutrophils | 7 (5-11) | 7 (4-9) | 0.315 | 6 (4-8) | 9 (6—11) | 0.022 |
| Creatinine | 102 (86-119) | 105 (90-124) | 0.644 | 102 (86-118) | 102 (87-127) | 0.647 |
| CRP | 52 (22-121) | 24 (15-58) | 0.046 | 40 (16-104) | 43 (18-100) | 0.846 |
| D-dimer | 1 (0-3) | 1 (0-3) | 0.544 | 1 (0-3) | 2 (1-3) | 0.181 |
| PCT | 0 (0-1) | 0 (0-1) | 0.660 | 0 (0-1) | 0 (0-1) | 0.340 |
| COVID-19 treatment protocols | ||||||
| Antibiotics (n, %) | 13 (81.2 %) | 14 (56 %) | 0.486 | 8 (80%) | 25 (71.4%) | 0.587 |